Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

463 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.
Duchmann M, Braun T, Micol JB, Platzbecker U, Park S, Pilorge S, Beyne-Rauzy O, Vey N, Sébert M, Gruson B, Dumas PY, Guieze R, Chretien ML, Laribi K, Chait Y, Legros L, Sahnes L, Hirsch P, Salanoubat C, Solary E, Fenaux P, Itzykson R. Duchmann M, et al. Among authors: hirsch p. Blood Cancer J. 2017 May 12;7(5):e562. doi: 10.1038/bcj.2017.41. Blood Cancer J. 2017. PMID: 28498370 Free PMC article. No abstract available.
Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients.
Rahmé R, Thomas X, Recher C, Vey N, Delaunay J, Deconinck E, Hirsch P, Bordessoule D, Micol JB, Stamatoullas A, Mariette C, Pautas C, Bories P, Marolleau JP, Hunault-Berger M, Fegueux N, Raffoux E, Dombret H, Degos L, Fenaux P, Adès L. Rahmé R, et al. Among authors: hirsch p. Leukemia. 2014 Dec;28(12):2422-4. doi: 10.1038/leu.2014.240. Epub 2014 Aug 21. Leukemia. 2014. PMID: 25142818 No abstract available.
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.
Vidal V, Robert G, Goursaud L, Durand L, Ginet C, Karsenti JM, Luciano F, Gastaud L, Garnier G, Braun T, Hirsch P, Raffoux E, Nloga AM, Padua RA, Dombret H, Rohrlich P, Ades L, Chomienne C, Auberger P, Fenaux P, Cluzeau T. Vidal V, et al. Among authors: hirsch p. Oncotarget. 2017 Jul 18;8(29):47103-47109. doi: 10.18632/oncotarget.17482. Oncotarget. 2017. PMID: 28514758 Free PMC article.
Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation.
Bonnet P, Chasset F, Moguelet P, Abisror N, Itzykson R, Bouaziz JD, Hirsch P, Barbaud A, Haroche J, Mekinian A, Hélias-Rodzewicz Z, Clappier E, Fenaux P, Fain O, Tazi A, Emile JF; MINHEMON and EMSED. Bonnet P, et al. Among authors: hirsch p. Haematologica. 2019 Nov;104(11):e530-e533. doi: 10.3324/haematol.2019.223552. Epub 2019 Jun 20. Haematologica. 2019. PMID: 31221777 Free PMC article. No abstract available.
Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy.
Cerrano M, Duchmann M, Kim R, Vasseur L, Hirsch P, Thomas X, Quentin S, Pasanisi J, Passet M, Rabian F, Rahmé R, Lengliné E, Raffoux E, Dhédin N, Sébert M, Maarek O, Raimbault A, Celli-Lebras K, Adès L, Fenaux P, Boissel N, Delhommeau F, Soulier J, Dombret H, Clappier E, Sujobert P, Itzykson R. Cerrano M, et al. Among authors: hirsch p. Leukemia. 2021 Mar;35(3):712-723. doi: 10.1038/s41375-020-0932-8. Epub 2020 Jun 24. Leukemia. 2021. PMID: 32581253
Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients.
Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E, Lacombe V, Terriou L, Ardois S, Bouaziz JD, Mathian A, Le Guenno G, Aouba A, Outh R, Meyer A, Roux-Sauvat M, Ebbo M, Zhao LP, Bigot A, Jamilloux Y, Guillotin V, Flamarion E, Henneton P, Vial G, Jachiet V, Rossignol J, Vinzio S, Weitten T, Vinit J, Deligny C, Humbert S, Samson M, Magy-Bertrand N, Moulinet T, Bourguiba R, Hanslik T, Bachmeyer C, Sebert M, Kostine M, Bienvenu B, Biscay P, Liozon E, Sailler L, Chasset F, Audemard-Verger A, Duroyon E, Sarrabay G, Borlot F, Dieval C, Cluzeau T, Marianetti P, Lobbes H, Boursier G, Gerfaud-Valentin M, Jeannel J, Servettaz A, Audia S, Larue M, Henriot B, Faucher B, Graveleau J, de Sainte Marie B, Galland J, Bouillet L, Arnaud C, Ades L, Carrat F, Hirsch P, Fenaux P, Fain O, Sujobert P, Kosmider O, Mekinian A; French VEXAS group; GFEV, GFM, CEREMAIA, MINHEMON. Georgin-Lavialle S, et al. Among authors: hirsch p. Br J Dermatol. 2022 Mar;186(3):564-574. doi: 10.1111/bjd.20805. Epub 2021 Nov 28. Br J Dermatol. 2022. PMID: 34632574 Free article.
Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series.
Martin de Frémont G, Hirsch P, Gimenez de Mestral S, Moguelet P, Ditchi Y, Emile JF, Senet P, Georgin-Lavialle S, Hanslik T, Maurier F, Adedjouma A, Abisror N, Mahevas T, Malard F, Adès L, Fenaux P, Fain O, Chasset F, Mekinian A. Martin de Frémont G, et al. Among authors: hirsch p. Front Immunol. 2021 Oct 4;12:715053. doi: 10.3389/fimmu.2021.715053. eCollection 2021. Front Immunol. 2021. PMID: 34671345 Free PMC article.
Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.
Duployez N, Largeaud L, Duchmann M, Kim R, Rieunier J, Lambert J, Bidet A, Larcher L, Lemoine J, Delhommeau F, Hirsch P, Fenwarth L, Kosmider O, Decroocq J, Bouvier A, Le Bris Y, Ochmann M, Santagostino A, Adès L, Fenaux P, Thomas X, Micol JB, Gardin C, Itzykson R, Soulier J, Clappier E, Recher C, Preudhomme C, Pigneux A, Dombret H, Delabesse E, Sébert M. Duployez N, et al. Among authors: hirsch p. Blood. 2022 Aug 18;140(7):756-768. doi: 10.1182/blood.2021015328. Blood. 2022. PMID: 35443031 Free PMC article.
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study.
Heiblig M, Ferrada MA, Koster MJ, Barba T, Gerfaud-Valentin M, Mékinian A, Coelho H, Fossard G, Barraco F, Galicier L, Bienvenu B, Hirsch P, Vial G, Boutin AB, Galland J, Le Guenno G, Bigot A, Warrington KJ, Kermani TA, Grayson PC, Patel BA, Beck DB, Jamilloux Y, Fenaux P, Sujobert P. Heiblig M, et al. Among authors: hirsch p. Blood. 2022 Aug 25;140(8):927-931. doi: 10.1182/blood.2022016642. Blood. 2022. PMID: 35609174 Free PMC article.
Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases.
Jachiet V, Ricard L, Hirsch P, Malard F, Pascal L, Beyne-Rauzy O, Peterlin P, Maria ATJ, Vey N, D'Aveni M, Gourin MP, Dimicoli-Salazar S, Banos A, Wickenhauser S, Terriou L, De Renzis B, Durot E, Natarajan-Ame S, Vekhoff A, Voillat L, Park S, Vinit J, Dieval C, Dellal A, Grobost V, Willems L, Rossignol J, Solary E, Kosmider O, Dulphy N, Zhao LP, Adès L, Fenaux P, Fain O, Mohty M, Gaugler B, Mekinian A; MINHEMON: French Network of dysimmune disorders associated with hemopathies. Jachiet V, et al. Among authors: hirsch p. Clin Exp Med. 2023 Jul;23(3):803-813. doi: 10.1007/s10238-022-00866-5. Epub 2022 Aug 11. Clin Exp Med. 2023. PMID: 35953763
463 results